As­traZeneca's Farx­i­ga gets rough FDA re­view date for ground­break­ing move in­to chron­ic kid­ney dis­ease

As­traZeneca’s Farx­i­ga broke ground last year with an FDA nod for heart fail­ure pa­tients with or with­out type 2 di­a­betes — a first-in-class ap­proval. But Farx­i­ga isn’t done in­no­vat­ing and is now look­ing at a ap­proval in the com­ing months in an­oth­er po­ten­tial block­buster in­di­ca­tion.

The FDA will re­view As­traZeneca’s ap­pli­ca­tion to take SGLT2 in­hibitor Farx­i­ga in­to chron­ic kid­ney dis­ease some­time in the sec­ond quar­ter af­ter tag­ging the drug for pri­or­i­ty re­view, the British drug­mak­er said Wednes­day. CKD is be­lieved to cur­rent­ly af­fect rough­ly 37 mil­lion US pa­tients, As­traZeneca said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER